JP6824960B2 - 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法 - Google Patents

細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法 Download PDF

Info

Publication number
JP6824960B2
JP6824960B2 JP2018505427A JP2018505427A JP6824960B2 JP 6824960 B2 JP6824960 B2 JP 6824960B2 JP 2018505427 A JP2018505427 A JP 2018505427A JP 2018505427 A JP2018505427 A JP 2018505427A JP 6824960 B2 JP6824960 B2 JP 6824960B2
Authority
JP
Japan
Prior art keywords
minicells
cell
cells
mini
minicell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018505427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522036A (ja
JP2018522036A5 (cg-RX-API-DMAC10.html
Inventor
ジェイ． ジャカローン，マシュー
ジェイ． ジャカローン，マシュー
エイチ． ワード，ゲイリー
エイチ． ワード，ゲイリー
Original Assignee
バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー
バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー, バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー filed Critical バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー
Publication of JP2018522036A publication Critical patent/JP2018522036A/ja
Publication of JP2018522036A5 publication Critical patent/JP2018522036A5/ja
Priority to JP2021003185A priority Critical patent/JP7568519B2/ja
Application granted granted Critical
Publication of JP6824960B2 publication Critical patent/JP6824960B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/08—Radiation
    • A61L2/081—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
JP2018505427A 2015-08-04 2016-08-03 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法 Active JP6824960B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021003185A JP7568519B2 (ja) 2015-08-04 2021-01-13 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200903P 2015-08-04 2015-08-04
US62/200,903 2015-08-04
PCT/US2016/045400 WO2017024059A1 (en) 2015-08-04 2016-08-03 Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021003185A Division JP7568519B2 (ja) 2015-08-04 2021-01-13 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法

Publications (3)

Publication Number Publication Date
JP2018522036A JP2018522036A (ja) 2018-08-09
JP2018522036A5 JP2018522036A5 (cg-RX-API-DMAC10.html) 2019-09-19
JP6824960B2 true JP6824960B2 (ja) 2021-02-03

Family

ID=57943608

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018505427A Active JP6824960B2 (ja) 2015-08-04 2016-08-03 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法
JP2021003185A Active JP7568519B2 (ja) 2015-08-04 2021-01-13 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021003185A Active JP7568519B2 (ja) 2015-08-04 2021-01-13 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法

Country Status (7)

Country Link
US (3) US10124024B2 (cg-RX-API-DMAC10.html)
EP (1) EP3331575A4 (cg-RX-API-DMAC10.html)
JP (2) JP6824960B2 (cg-RX-API-DMAC10.html)
KR (2) KR102687638B1 (cg-RX-API-DMAC10.html)
CN (2) CN108348624B (cg-RX-API-DMAC10.html)
AU (1) AU2016301302B2 (cg-RX-API-DMAC10.html)
WO (1) WO2017024059A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098163A1 (en) 2016-11-23 2018-05-31 Vaxiion Therapeutics, Llc Immunomodulatory & oncolytic minicells and methods of use
US11624061B2 (en) 2017-04-28 2023-04-11 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112019022539A2 (pt) 2017-04-28 2020-06-16 Agrospheres, Inc. Composições e métodos para o encapsulamento e entrega escalonável de agorquímicos
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
US20230044257A1 (en) * 2019-12-23 2023-02-09 Agrospheres, Inc. Compositions and methods for enhanced uptake of active ingredients for animal health and nutrition
MX2022014531A (es) 2020-05-21 2023-03-03 Coherus Biosciences Inc Sistemas y metodos para producir dispositivos de inyeccion esteriles.
CN116723765A (zh) * 2020-12-11 2023-09-08 农业球体公司 用于可扩展大规模生产微细胞的生物处理系统和方法
WO2022215495A1 (ja) * 2021-04-08 2022-10-13 株式会社カネカ 環状リポペプチド化合物のバイオバーデンの低減方法
CN117618602A (zh) * 2023-12-18 2024-03-01 苏州尔生生物医药有限公司 一种负载癌细胞裂解物组分的癌症粒子疫苗的终端灭菌方法及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131920A (ja) 1982-01-29 1983-08-06 Nisshin Flour Milling Co Ltd 鶏の大腸菌症の予防法
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
AU4090299A (en) 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030166099A1 (en) 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins
US20030207833A1 (en) 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
AU2003296086A1 (en) 2002-12-26 2004-07-22 Nitto Boseki Co., Ltd. Immunoassay method and kit to be used therein
WO2004069255A2 (en) * 2003-02-04 2004-08-19 Mcmaster University Use of quinazoline derivatives or other compounds for inhibiting dihydrofolate reduxtase; screening assay for the identification of novel therapeutics and their cellular targets
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
ATE501735T1 (de) 2003-12-09 2011-04-15 Engeneic Molecular Delivery Pty Ltd Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen
WO2005058333A1 (de) * 2003-12-18 2005-06-30 Owen Holding Ltd Methode zur gewinnung eines biologisch aktiven mit elektroschock behandelten blutserums und seine verwendung
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
EP1718338B1 (en) 2004-02-02 2015-05-06 EnGeneIC Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
WO2006055024A2 (en) 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
CN102921019B (zh) 2004-08-26 2015-04-01 恩杰内克分子递送有限公司 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸
US9358292B2 (en) * 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
WO2009012493A2 (en) 2007-07-19 2009-01-22 The Board Of Regents Of The University Of Oklahoma H-antigen binding polypeptides and methods of use
US8236538B2 (en) * 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
CA2729545C (en) 2008-06-25 2019-07-09 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
JP2012508582A (ja) 2008-11-14 2012-04-12 マリーナ バイオテック，インコーポレイテッド β−カテニンの大腸菌（Ｅ．ｃｏｌｉ）介在遺伝子サイレンシング
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
CN102349978A (zh) * 2011-10-27 2012-02-15 天津中新药业集团股份有限公司达仁堂制药厂 生血丸在制备预防低剂量电离辐射致细胞损伤药物中的应用
KR102485491B1 (ko) 2012-10-02 2023-01-04 벡션 테라퓨틱스 엘엘씨 면역 조절성 미니세포 및 사용 방법
WO2018098163A1 (en) * 2016-11-23 2018-05-31 Vaxiion Therapeutics, Llc Immunomodulatory & oncolytic minicells and methods of use

Also Published As

Publication number Publication date
EP3331575A1 (en) 2018-06-13
US11564953B2 (en) 2023-01-31
CN108348624A (zh) 2018-07-31
KR20230111275A (ko) 2023-07-25
KR102558941B1 (ko) 2023-07-21
JP2018522036A (ja) 2018-08-09
US20190282629A1 (en) 2019-09-19
KR102687638B1 (ko) 2024-07-22
US20230321159A1 (en) 2023-10-12
US10124024B2 (en) 2018-11-13
US12427172B2 (en) 2025-09-30
AU2016301302A1 (en) 2018-03-08
CN113577323A (zh) 2021-11-02
AU2016301302B2 (en) 2023-01-12
JP7568519B2 (ja) 2024-10-16
KR20180056642A (ko) 2018-05-29
EP3331575A4 (en) 2019-03-27
CN108348624B (zh) 2021-07-27
US20180153942A1 (en) 2018-06-07
JP2021059600A (ja) 2021-04-15
CN113577323B (zh) 2024-02-20
WO2017024059A8 (en) 2017-06-29
WO2017024059A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
JP7568519B2 (ja) 細菌由来ミニ細胞型バイオ医薬品の電離放射線照射滅菌およびその使用方法
US10919942B2 (en) Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
US10280425B2 (en) Minicircle DNA recombinant parental plasmid having genetically engineered antibody gene expression cassette, a minicircle DNA having the expression cassette, and applications
US20220054585A1 (en) Immunomodulatory & oncolytic minicells and methods of use
US20250339518A1 (en) Dual sting/rig-i agonist oncolytic minicells as in situ immunization agents and methods of use
CN121985958A (zh) 用于多模式分泌新抗原的基因改造细菌

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210113

R150 Certificate of patent or registration of utility model

Ref document number: 6824960

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250